Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by TAXIS Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TXA709

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Boston University

            Deal Size: $14.6 million Upfront Cash: $3.2 million

            Deal Type: Funding January 14, 2020

            Details:

            Funding aims to develop Efflux Pump Inhibitors (EPIs), representing a new drug class designed to address a major mechanism of multi-drug-resistant (MDR) Pseudomonas aeruginosa bacteria.